Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anyone have any clue as to float, authorized and outstanding shares? These are some interesting spikes. Are they planning on making a comeback? How does a stock that was on ice for years all the sudden start trading again without something being afoot?
I'm in tomorrow.
I don't even recall this purchase eons ago but, but my stock alerts went nuts a month ago when this thing woke from cryostasis and registered a 1.5M share purchase. Volume has slowly started to pickup and today it's happened a third time and that's what I call a charm.
I'm tempted to buy some shares here dirt cheap, but in curious to know what is going on. Is the company still around? Reverse merger?
Why would this suddenly come to life?
With these 1M + monster sells the past 4-5 days, someone is unloading a sh*t ton of shares. Hope it's not major dilution.
Then again, i've been buying on dips so I guess I can't complain. In the end, I envision share price in the Oct-Dec 2015 time frame and I can't help but smile.
Thanks for posting.
Slow and steady. Tune out the nitwits focusing on half penny dips and focus on the big picture.
Catalano will be part of a conference involving multiple 800 lb. biotech gorillas. What's more? He was invited.
Put that in your pipe and smoke it, Attote and 'Econ Student' (cue: snickers).
LoL.
I see the forest, not the trees on OXIS. Thanks, but I'm good.
Make or break day? Lol. I suppose if you are a trader. I'm holding and adding on dips for 2015.
It takes just one piece of news to send this thing to the moon.
Econ student, I thought you were here to educate us and to help is from falling into the same traps you did over the years. Lol. Why so negative, then?
In for another 75k. Thanks for the discount. holding long.
HAHA. Econ Student just got taken to school--again.
Remember when it first showed up? Guys, I'm just here to help you. LOL.
Looking forward to watching Econ Student get taken to school again, and again, and again.
Sweet, kinda like double secret probation?
Upon resumption of trading, the shares will trade in a double call auction trading mode (fixing) rather than the continuous trading mode formerly applicable to Oxis shares.
Hmmmm. That was quick. What was the point of it was going to last a week?
OXIS’ IMMUNOTHERAPEUTIC DEVELOPMENT STRATEGY
Published on 01st April
Editorial Team
Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc. discussed during its March 31, 2015 conference call with shareholders, analysts and other interested parties its immunotherapeutic development strategy.
During the teleconference, Anthony J. Cataldo, Chairman and Chief Executive Officer stated that Oxis Biotech is focused on developing immunotherapies for the treatment of triple-negative breast cancer (TNBC), multiple myeloma and associated osteolytic lesions which are significant unmet medical needs. The development includes OXS-2175 (TNBC) and OXS-4235 (multiple myeloma) are also being developed as antibody-drug conjugates.
Antibody-drug Conjugates
As part of it’s development program, the company is pursing targeted immunotherapies with its partner MultiCell Immunotherapeutics. MultiCell ‘s proprietary antibody-drug conjugate platform technology is based on unique multivalent, cleavable linkers that allow tethered drugs to be released intracellularly or extracellularly upon binding of the antibody to the target cell. Furthermore, MultiCell’s linkers are designed to attach multiple drugs per targeting antibody, and to release the drugs in their original form without modification of the drug. An example of an FDA-approved ADC is brentuximab vedotin (Adcetris®; Seattle Genetics) for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL).
Bispecific immune cell engagers
In additional to developing traditional ADCs, Oxis Biotech is also developing bispecific immune cell engagers, a class of monoclonal antibodies that direct a person’s immune system to attack cancer cells. More specifically, bispecific immune cell engagers consist of the part of the monoclonal antibody which recognizes an immune cell such as a cytotoxic T-cell, and the part of a different monoclonal antibody which recognizes the cancer cell. When administered as a therapeutic, the bispecific immune cell engager brings cytotoxic T-cells in contact with the target cancer cell where the cytotoxic T-cell kills the cancer cell. An example of a bispecific immune cell engager is the recent FDA-approved drug blinatumomab (Blincyto®; Amgen) for the treatment of acute lymphoblastic leukemia (ALL).
Oxis Biotech develops innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS’ lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer.
In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis. OXIS’ lead drug candidate, OXS-4235, also a small molecule therapeutic candidate targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.
Exciting developments
Commenting on the company’s development, Anthony J. Cataldo, Chairmen and Chief Executive Officer Oxis International, Inc./Oxis Biotech, Inc. noted “The first quarter of 2015 has been very exciting for Oxis and our shareholders. There is a lot going on inside Oxis and [we we’re happy to share these developments] so [our sharholders] can understand what all of the excitement is about. I am using the same approach that I used when, as founder, I created Lion Biotechnologies, Inc. which has enjoyed dramatic success. We have acquired intellectual property assets, brought world class scientists on board, completed financings, and partnered with some of the best medical research facilities in the world. Oxis, has grown dramatically and achieved significant milestones recently.”
1000% in a single day never smelled sooooo good. Fong is Aces.
Given the breadth of the MCIT License and Research Agreements, I'll wager (actually I have by buying OXIS stock) that OXIS is one of the four drug development programs in reserve or 1 of the 11 still under consideration.
My $.02; It's the EMA and not the FDA.
---------
• Adaptive Licensing is a highly current topic. In March 2014, the EMA (European Medicines Agency) began to invite drug developers to apply for involvement in the pilot projects.
• Currently, two drug development programs have been accepted by the EMA as pilots. Three were rejected, four are in reserve and 11 are still under consideration.
• AL is part of a suite of global initiatives with shared features. These include: Staggered Approval, Progressive Authorisation, Conditional Licensing and, more recently, Medicines Adaptive Pathways (MAPs) or Medicines Adaptive Pathways to Patients (MAPPs).
• The high level of variance in AL approaches and scarcity of practical information justifies the need for an unbiased report of the strengths, weaknesses and opportunities for this system.
• If pilots are successful, AL may become more widely used across all regions, and also play an important role in shaping future regulatory policy, with the potential to affect all healthcare stakeholders.
• This new CBR report examines all existing information, and builds on that with conference attendance and new primary research with KOLs and figures central to the movement. It creates a balanced view, and provides an understanding of the current status and potential implications.
Hoping that's the case. The MCIT deal runs only 18 months; OXIS has already made payments (as of this coming Friday) of $600,000 on the $1.625M due for the Research & License Agreements. I know that Cataldo has been selling his LBIO up lift to Nasdaq as serious bona fides w/OXIS--and it is--but I'd much rather that shareholder value be increased as a result of the technology(s) OXIS has at its disposal.
I don't want management thinking about gunning for LBIO-type valuation; I want them gunning for GWPH-type valuation.
Fingers crossed on the promising research.
I hope OXIS has news soon. And I hope it concerns Adaptive Pathways and/or FDA...preferably before Catalano attempts to uplift. There would be a big difference to shareholders if the uplift happened before tangible news. Fingers crossed.
You make me chuckle.
Yes THE 10-K NOT OUT YET!!!
No, it's not. And when it is, I look forward to learning more about this:
As a result of the acquisition of Brawnstone Security, LLC in July 2014, the Company anticipates a significant change in the results of operations for the year ended December 31, 2014 versus December 31, 2013. The Company has not completed the financial statements necessary to provide a reasonable estimate of the change in the results of operations, however, the Company anticipates a significant increase in revenue from the operations of Brawnstone with changes in operating losses.
Wait until revised 10-K comes out this week. You'll have your answer. Given the small float and the potential in the 10-K, I don't think its unreasonable at all to expect momo to continue.
Some pretty sizeable buys coming in right now. wow.
I am keeping on eye on Edgar for their revised 10-K filing. The prior two late filings have dropped between 6-8 days after original filing, between 2-3 PM EST I believe. Is would icing on the cake if it were to become available today, before what I am learning is called power hour. Lol. Worst case it arrives no later than next Wednesday. Outside of any new PR's updating company status, this should provide some interesting and positive discussion:
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
As a result of the acquisition of Brawnstone Security, LLC in July 2014, the Company anticipates a significant change in the results of operations for the year ended December 31, 2014 versus December 31, 2013. The Company has not completed the financial statements necessary to provide a reasonable estimate of the change in the results of operations, however, the Company anticipates a significant increase in revenue from the operations of Brawnstone with changes in operating losses.
LoL. Are you really even posting right now?
Be still my beating heart! lol. I won't hold my breath but fingers crossed. Still would really be a good time in the next day or two to update the filing. I think the Brawnstone numbers will start to fill in a newly evolving FFFC with low float and more defined mission. That Chong piece was well done.
What does seeing silver mean?
I want to see this late filing completed soon:
As a result of the acquisition of Brawnstone Security, LLC in July 2014, the Company anticipates a significant change in the results of operations for the year ended December 31, 2014 versus December 31, 2013. The Company has not completed the financial statements necessary to provide a reasonable estimate of the change in the results of operations, however, the Company anticipates a significant increase in revenue from the operations of Brawnstone with changes in operating losses.
I think the Yahoo interview yesterday was strong and added a level of gravitas for FFFC, which had been pretty beaten up as of late. It would be nice to see what positive impact Brawnstone has had on FFFC.
L2 looking better this morning.
34 million Shares outstanding I belive. Not more. 2014 10k, late, will be filed in the next few days. FONG already indicated it would show higher revenue and lower debt than is currently reported.
Stock hasn't burmed a lot of daily activity since the reverse split so this could be a really good opportunity. Fingers crossed. Good luck.
I believe $2, which might be the min requirement to get on Nasdaq. LBIO is now trading at over $12 a share so I would not worry about Econ Student is blathering about.
Try Googling LBIO, Genesis and Up lifting. There are a couple of articles on uplifting. Interesting story.
Fingers crossed. GLTYA.
BILLIONS of WORTHLESS SHARES with HUGE DEBT!
WRONG.
No more than 34 MILLION shares outstanding. Do you homework.
Those debt numbers are being revised with filing. And its not necessarily the dispensaries that worry about cash, but the individual consumer...HELLO?
Not going to waste another minute going back and forth, LOL...catch you on the flip side.
People dump a stock on a reverse split because 95% of the time, the stock is a dog. Jumping to the NASDAQ and attracting large institutional investors? C'mon, I really don't have to explain this, do I?
Tommorrow is going to be very, very interesting, to say the least. Whooda thought Chong would truly collaborate with Fong, about a bong, with coverage on Yahoo finance. Giddy. Up.
Lured by Deceptions, you like apples?
How 'bout them apples?
http://finance.yahoo.com/news/tommy-chong-s-solution-for-pot-s-banking-problem-163016679.html
Incorrect. Genesis was at $.02 which required 100 to 1 reverse. Right now, it would be 50-1. And as an Econ Student, surely you can't be that dumb to argue all the positives and zero negatives associated with up lifting.
Where do you jokers come from? Honestly.
The last two times they filed a late notice, between the 6th and 7th day the filed the updated numbers. We could see an update as early as tomorrow. Otherwise, they have to file by the 15th. So we'll have news of some sort in the next week.
If Fong actually expects higher income and lower debt as a result of Brownstone, I sure hope he issues a release to let everyone know. Either way, something will be happening very soon.
Fingers crossed it's good news!
And Watching Level 2, it takes almost nothing to move this puppy north on very limited volume. Tells me there are not millions and millions of shares available.
Agreed. Lots of buys!
Sure would be nice to get a updated annual report. Better yet if the package a release with it. I've been watching this over the past few months. Since the reverse split there has not been tons of dumping.
I think if FONG isbthe dumper everyone says he is, I have to believe give the small float, he's probably going to take advantage of great news and get share price up so he can get cash to help the business acquire.
Holding and looking for news. GLTYA.
Agreed. To me, this is actually a no-brainer. Low float and already been told revenue is going to increase and corp debt decrease.
Bring in the news. I have been adding incrementally. Smart play imho.
LoL, thanks for the chuckle. Blame yourself if you lost money.
And with that folks, I am off for the long weekend. Happy Easter to all.